tiprankstipranks
AstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02
The Fly

AstraZeneca says Enhertu met prespecified criteria for ORR in DESTINY-PanTumor02

Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo’s Enhertu met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients, AstraZeneca announced. Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. The DESTINY-PanTumor02 Phase II trial is evaluating the efficacy and safety of Enhertu in patients with locally advanced, unresectable, or metastatic previously treated, HER2-expressing solid tumours not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers. The primary endpoint of the trial is investigator-assessed confirmed ORR and investigator-assessed duration of response, or DoR, is a key secondary endpoint. The data will be presented at an upcoming medical meeting and shared with global regulatory authorities. Reference Link

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AZN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles